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To clarify the impact of adherence, we treated 122 genotype 1 high viral titer chronic hepatitis C patients with pegylated interferon
(peg-IFN) and ribavirin for 48 weeks at nine referral hospitals, and evaluated the prognostic factors with a focus on the adherence
to the treatment. This study included 68 (55.7%) treatment-na¨ ıve patients and 54 (44.3%) patients who did not respond to the
previous treatment. Multivariate analysis revealed adherence to peg-IFN and ribavirin as the only signiﬁcant predictor. Sustained
virological response (SVR) rate was 72.2%, 19.0%, and 27.3% in patients given ≥80%, 60%–80%, and <60% dose peg-IFN,
respectively, and was 68.6%, 41.2%, and 5.3% in those given ≥80%, 60%–80%, and <60% dose ribavirin, respectively. SVR rate
sharply fell when exposure to peg-IFN was below 80% whereas it decreased in a stepwise manner as for ribavirin. Therefore, ≥80%
of peg-IFN and as much as possible dose of ribavirin are desired to achieve SVR in the treatment of genotype 1 high viral titer
chronic hepatitis C.
1.Introduction
Although the combination of pegylated interferon (peg-
IFN) and ribavirin (RBV) is the standard-of-care therapy for
chronic hepatitis C, the sustained virological response (SVR)
rate is still 40%–50% [1–3] for patients who are infected
with genotype 1 and have high viral load in their sera.
Adherence to the therapy is an important factor associated
with a favorable outcome. McHutchison et al. reported that
the patients who received ≥80% of the scheduled doses of
peg-IFN and RBV for ≥80% of the planned duration of
therapy had an SVR rate of 51% compared with 34% in less
adherent patients [4]. In contrast, a study on patients with
advanced ﬁbrosis revealed that reducing RBV dose did not2 Hepatitis Research and Treatment
aﬀect SVR rate as long as peg-IFN dose was maintained [5].
Reddyetal.alsoreportedthatSVRratewasaﬀectedadversely
by RBV dose reduction when cumulative exposure was less
than 60%, and that RBV dose reduction raised the relapse
rate[6].Thesigniﬁcantimpactofadherencetobothpeg-IFN
and RBV on SVR is well understood, however, there may be
diﬀerence between these two drugs in the way they eﬀect the
response.
Until now, many host factors including younger age (40
years or less) [2], female gender [7], lighter body weight
[1, 2], the absence of insulin resistance [8], elevated ALT
levels [2], less advanced liver histology [2, 7], and non-
African American race [7, 9] are reported to be associated
with favorable response. Recently the association of genetic
variation of IL28B with response has been reported [10–12].
Japanese elderly women were reported to be resistant to
this therapy [13, 14]. Japanese patients are approximately 10
years older than those in other countries and our reports
would provide useful information when considering therapy
for elderly patients in other countries. The lower SVR rate in
elderly women might be attributable to lower adherence to
peg-IFN or RBV. However, few studies analyzed relationship
between SVR rate and the adherence in elderly patients.
In this study, we treated genotype 1 high viral titer
chronic hepatitis C patients with peg-IFN and RBV combi-
nation therapy, and evaluated the prognostic factors with a
focus on the adherence to the treatment.
2.MaterialsandMethods
2.1. Patients. This study was performed at nine referral
hospitals. Patients with hepatitis C virus (HCV) geno-
type 1 and high viral load (≥100,000IU/mL) who received
peg-IFN alfa-2b (Pegintron, Schering-Plough Corporation,
Kenilworth, NJ) and RBV (Rebetol, Schering-Plough Cor-
poration) combination therapy for 48 weeks from January
2004 to December 2006 were consecutively enrolled into the
study. Exclusion criteria were as follows: (1) patients with
leukopenia (<3,000/μL), neutropenia (<1,500/μL), throm-
bocytopenia (<90,000/μL), or anemia (hemoglobin con-
centration <12g/dL), (2) patients with creatinine clearance
<50mL/min, and (3) existence of cirrhosis, autoimmune
diseases, uncontrolled mental disorders, uncontrolled malig-
nancy, or severe heart or lung diseases. Written informed
consent was obtained from all patients.
2.2. Treatment. The patients were given peg-IFN alfa-2b at
a dosage of 1.5mg/kg every week subcutaneously for 48
weeks. Daily RBV was administered orally for 48 weeks
according to the labeling approved by the Japanese Ministry
of Health, Labour and Welfare; 600mg for patients ≤60kg,
800mg for patients weighing 60 to 80kg, and 1000mg for
patients >80kg. The use of hematopoietic growth factors
such as G-CSF and erythropoietin was not permitted in
this study. Blood samples were collected every four weeks
and parameters including complete blood cell counts, bio-
chemistries, and the amount of HCV-RNA were determined.
HCV serotype was tested with a serological genotyping assay
kit(ImmunocheckF-HCVGrouping;InternationalReagents
Co., Tokyo, Japan) [15]. If HCV serotype was not deﬁnitive,
HCVgenotypingwasperformed(HCVCoreGenotype;SRL,
Tokyo, Japan). The response to the treatment was evaluated
by an intention-to-treat analysis.
2.3.StatisticalAnalysis. ThefactorsassociatedwithSVRwere
analyzed by logistic regression using SPSS version 16 (SPSS
Japan, Tokyo, Japan). Univariate or multivariate logistic
regression analyses were performed to establish the factors
contributing to SVR. All reported P-values are 2-sided, with
P<. 05 considered statistically signiﬁcant. The diﬀerence in
the rates of relapse or SVR was evaluated by chi-square test.
3. Results
3.1. SVR. A total of 122 patients were enrolled into the
study. Forty-ﬁve patients (36.9%) were female and mean ±
standard deviation (S.D.) of age was 54.0 ± 10.6( m i n
19–max 70) years. Sixty-eight patients (55.7%) were na¨ ıve
patients. The mean ± S.D. of weight and body mass index
(BMI) was 63.5 ± 11.2kgand23.7 ± 3.3, respectively. High
(100,000–800,000IU/mL) and very high (≥800,000IU/mL)
HCV-RNA levels were observed in 36 (29.5%) and 86
(70.5%) patients, respectively. This study included 68
(55.7%) treatment-na¨ ıve patients and 54 (44.3%) patients
whodidnotrespondtotheprevioustreatment.Theprevious
treatmentincludeda24-weekcourseofIFNalfa-2bandRBV
combination therapy for 36 patients and a 24-week course
of IFN alfa-2b or natural IFN alfa (human lymphoblastoid
IFN) monotherapy for 18 patients. Forty-seven patients
relapsed after the discontinuation of treatment, and the
other 7 patients were nonresponders, in whom serum HCV-
RNA were positive throughout the treatment. The SVR
rate was 60.3%, 51.1%, and 28.6% in na¨ ıve patients, those
with relapse, and nonresponders, respectively. In this study,
the SVR rate was not signiﬁcantly diﬀerent between na¨ ıve
patients and those treated previously. Liver biopsy was
performed before treatment in 87 (71.3%) patients; 75
(86.2%) and 12 (13.8%) patients revealed METAVIR ﬁbrosis
score of 0–2 and 3-4, respectively. The SVR rate was not
signiﬁcantly diﬀerent between these two groups; 57.3% in
patients with F0–2 and 41.7% in those with F3-4. Finally 67
patients (54.9%) achieved SVR in the entire cohort.
3.2. Factors Associated with SVR (Table 1). Analyzed factors
included gender, age, body weight, BMI, viral load, history
of IFN treatment, and adherence to the treatment. Younger
age, heavier weight, lower viral load, peg-IFN adherence,
and RBV adherence were signiﬁcant factors associated with
SVR by univariate analysis. Multivariate analysis revealed
adherence to peg-IFN and adherence to RBV as a signiﬁcant
predictor. We performed the same analysis after stratifying
treatment-na¨ ıve and previously treated patients, and found
adherence to peg-IFN and RBV as only factors signiﬁcantly
associated with SVR (data not shown) as shown in the entire
cohort.
Patients given ≥80% dose of scheduled peg-IFN were
more likely to achieve SVR by 7.7-fold (95% CI; 1.926–
30.798, P = .004) than those given 60%–80% dose. The SVRHepatitis Research and Treatment 3
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Figure 1: Scatter plot of patients with or without SVR according
to administered total doses of peg-IFN and RBV. One hundred %
represents a full scheduled dose. A circle and a triangle indicate
a patient with SVR and one without SVR, respectively. A number
represents number of patients with SVR/total number (SVR rate).
rate in patients given 60%–80% dose peg-IFN was similar
with those given <60% dose. Patients given ≥80% dose
and those given 60%–80% dose of scheduled RBV were
more likely to obtain SVR than those given <60% by 27.4-
fold (95% CI; 3.130–240.151, P = .003) and by 15.7-
fold (95% CI; 1.289–190.653, P = .031), respectively.
The outcome of each case was shown in a scatter plot
(Figure 1). The SVR was 1/19 (5.3%), 7/17 (41.2%), and
59/86(68.6%)inpatientsgiven<60%,60%–80%,and ≥80%
of total RBV dose, respectively (Figure 2). Therefore, the
more RBV was administered, the higher was the SVR rate.
On the other hand, SVR was achieved in 6/22 (27.3%), 4/21
(19.0%), and 57/79 (72.2%) patients given <60%, 60%–
80%, and ≥80% of total peg-IFN dose, respectively. Peg-
IFN dose of 80% or more was important to obtain SVR.
Notably none of the patients who received <80% dose for
both drugs resulted in SVR (Figure 1). The relationship
between SVR and adherence was analyzed separately in the
treatment-na¨ ıve group and the previously treated group. In
the treatment-na¨ ıve group the SVR rate was 74.5%, 20.0%,
and 36.4% in patients given ≥80%, 60%–80%, and <60%
dose peg-IFN, respectively, and was 74.5%, 54.5%, and 0%
in those given ≥80%, 60%–80%, and <60% dose RBV,
respectively. In the previously treated group, SVR rate was
68.8%, 18.2%, and 18.2% in patients given ≥80%, 60%–
80%, and <60% dose peg-IFN, respectively, and was 61.3%,
33.3%, and 11.1% in those given ≥80%, 60–80%, and <60%
dose RBV, respectively. These trends were similar with the
results obtained from the entire cohort.
There was a trend that younger patients received greater
peg-IFNdose;72/106(67.9%)patientsyoungerthan65years
a n d7 / 1 6( 4 3 . 8 % )p a t i e n t sa g e d6 5o ro l d e rr e c e i v e d≥80% of
total peg-IFN dose (P = .059).
Sixty-six patients (54.1%) received ≥80% dose for both
drugs. Of these 49 (74.2%) patients resulted in SVR. When
analysis was performed in these patients, no signiﬁcant
factors associated with SVR were chosen.
3.3. Rapid Virological Response (RVR), Early Virological
Response (EVR), and Relapse. The population of patients
whose serum HCV-RNA ﬁrst disappeared at week 4 (RVR),
week 8, week 12 (EVR), week 24, and week 48 was 10 (8.2%),
39 (32.0%), 28 (23.0%), 20 (16.4%), and 4 (3.3%) patients,
respectively. Twenty-one (17.2%) patients were positive for
HCV-RNA throughout the treatment period (null response).
The SVR rate of these patients who became negative for
HCV-RNA at week 4 (RVR), week 8, week 12 (EVR), week
24, and week 48 was 10/10 (100%), 35/39 (89.7%), 17/28
(60.7%), 5/20 (25%), and 0/4 (0%), respectively. In 101
patients negative for HCV-RNA at the end of treatment,
34 (33.7%) patients relapsed. Relapse rate was signiﬁcantly
lower in patients who received ≥80% dose of peg-IFN than
that in those who received 60%–80% or <60% dose (18.6%
in patients with ≥80% dose versus 69.2% in those with
60%–80% dose (P<. 001) and 66.7% in those with <60%
dose (P<. 001), Figure 3). The relapse rate increased in a
stepwise fashion according to the adherence to RBV (91.7%
in patients with <60% dose versus 41.7% in those with 60%–
80% dose (P<. 05), and versus 23.4% in those with ≥80%
dose (P<. 001)). These results were inversely associated with
SVR rates.
3.4. Adverse Eﬀect. Seventeen (13.9%) patients discontinued
treatment. The reasons of premature discontinuation were
general fatigue and/or appetite loss (11 patients), fundal
hemorrhage (1 patient), deterioration of diabetes mellitus (1
patient), and depression (1 patient). Three patients discon-
tinued treatment because of positive HCV-RNA at week 24.
Thirty-nine (32.0%) and 33 (27.0%) patients required dose
reduction of peg-IFN and RBV, respectively. Major reasons
of dose reduction were neutropenia or thrombocytopenia
for peg-IFN and anemia for RBV. Common adverse eﬀects
included general fatigue, appetite loss, weight loss, and pru-
ritus. In 12 patients with advanced liver disease (METAVIR
ﬁbrosis score of 3-4), 6 (50%) and 4 (33.3%) patients
required dose reduction of peg-IFN and RBV, respectively.
In 75 patients with milder liver disease (METAVIR ﬁbrosis
score of 0–2), 22 (29.3%) and 20 (26.7%) patients required
dose reduction of peg-IFN and RBV, respectively. There was
no signiﬁcant diﬀerence between these two groups in the
proportion of patients who required dose reduction.
4. Discussion
The mean age of our study population was 54.0 years, which
was approximately 10 years older than patients of major
studies in Western countries [1–3]. Our cohort consisted
of treatment-na¨ ıve patients (55.7%) and those who did not
respondtothepriortreatment(44.3%).SVRwasachievedin
54.9% patients.
In our study, adherence to peg-IFN and RBV was the
only signiﬁcant factor associated with SVR. Interestingly,4 Hepatitis Research and Treatment
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Figure 2: SVR rates classiﬁed by adherence to peg-IFN and RBV. ∗The SVR rate in patients with ≥80% dose of peg-IFN was signiﬁcantly
higher than that in those with <60% and 60%–80% (P<. 001 for both). #The SVR rate in patients with 60%–80% dose of RBV was
signiﬁcantly higher than that in those with <60% (P<. 05). ##The SVR rate in patients with ≥80% dose of RBV was signiﬁcantly higher than
that in those with <60% (P<. 001) and 60%–80% (P<. 05).
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Figure 3: Relapse rates classiﬁed by adherence to peg-IFN and RBV. ∗The relapse rate in patients with <60% and 60%–80% dose of peg-
IFN was signiﬁcantly higher than that in those with ≥80% (P<. 001 for both). #The relapse rate in patients with <60% dose of RBV was
signiﬁcantly higher than that in those with 60%–80% (P<. 05) and ≥80% (P<. 001).
the SVR rate stepwisely rose by the increase of administered
dose of RBV. In contrast, 80% or more dose of peg-IFN
was required to achieve SVR (Figure 2). This observation
resulted from the likelihood of relapse (Figure 3); higher
relapse ratewas documented in a stepwise fashion in patients
with smaller exposure to RBV, as previously suggested [16–
18]. SVR rate was 74.2% when both drugs were administered
≥80%. Notably none of the patients who received <80%
dose of both drugs attained SVR (Figure 1), conﬁrming
the validity of 80/80/80 rule together with ≥80% treatment
duration.
The diﬀerence between peg-IFN and RBV in the impact
of adherence on SVR, especiallywithin the <80% dose range,
is still unclear. In our study, SVR rate sharply fell when
exposure to peg-IFN was below 80% whereas it decreased
in a stepwise manner as for RBV. Hiramatsu et al. recently
reported that RBV dose reduction raised relapse rate in a
dose-dependent manner [19], which is in agreement with
our results.
At least 80% dose of peg-IFN will be necessary to obtain
favorable outcome. In contrast, RBV should be administered
as much as possible within the planned dose. To accomplish
this, RBV dose should be reduced by 200-mg decrements
when anemia appears, and restored to the previous dose
when anemia improves. Higher than standard dose RBV
giventogetherwithstandarddosepeg-IFNmayincreaseSVR
rate [20], however, safety issues such as severe anemia are
the major concern for this approach. Although the use of
erythropoietin contributes to maintain RBV dose, the eﬀect
on SVR has not been shown [21, 22].Hepatitis Research and Treatment 5
Table 1
Variables SVR P-value Adjusted OR (95% C.I.) P-value
Sex .091 .501
Female 20/45 (44.4%) 1.00
Male 47/77 (61.0%) 1.429 (0.506–4.032)
Age (yr) .019 .398
65< 5/16 (31.3%) 1.00
51< ≤64 35/68 (51.5%) 2.655 (0.581–12.132)
≤50 27/38 (71.1%) 2.695 (0.574–12.659)
Weight (Kg) .028 .116
<65 31/68 (45.6%) 1.000
65≤ 36/54 (66.7%) 3.053 (0.760–12.274)
BMI .716 .158
24≤ 30/57 (52.6%) 1.000
<24 37/65 (56.9%) 2.747 (0.674–11.236)
Viral load (IU/mL) .015 .174
800,000≤ 41/86 (47.7%) 1.000
100,000≤ <800,000 26/36 (72.2%) 2.137 (0.716–6.369)
History of IFN treatment .203 .581
yes 26/54 (48.1%) 1.000
no 41/68 (60.3%) 1.316 (0.496–3.493)
Peg-IFN adherence (%) <.001 .008
<60 6/22 (27.3%) 2.637 (0.448–15.513) .284
60≤ <80 4/21 (19.0%) 1.000 —
80≤ 57/79 (72.2%) 7.702 (1.926–30.798) .004
RBV adherence (%) <.001 .010
<60 1/19 (5.3%) 1.000 —
60≤ <80 7/17 (41.2%) 15.679 (1.289–190.653) .031
80≤ 59/86 (68.6%) 27.416 (3.130–240.151) .003
Sezakietal.reportedthatelderlywomenwereresistantto
peg-IFN and RBV combination therapy in Japan [13, 14]. In
our study, younger age was a signiﬁcant factor by univariate
analysis, however, neither gender nor age was signiﬁcantly
associated with SVR by multivariate analysis. There was a
trendtowardsloweradherencetopeg-IFNinelderlypatients.
Therefore, older age itself is not a signiﬁcant factor but is
related to dose reduction or discontinuation, as reported by
Iwasaki et al. [23].
SVR rate was 74.2% when both drugs were adminis-
tered ≥80%. Japanese patients are approximately 10 years
older than those in other countries and anticipated to be
vulnerable to adverse eﬀects. Therefore, the adjuvant therapy
that alleviates adverse eﬀects should be developed. We
recently demonstrated that maloxicam, a COX-2 inhibitor,
decreased the rate of patients who required dose reduction
by preventing the decrease of neutrophil counts [24].
In this study, serotyping was used instead of genotyping
becausegenotyping wasnot coveredbytheJapanesenational
health insurance. Serotype 1 includes genotype 1a and 1b.
Because genotype 1a is rarely observed in Japan [25], most
patients of this study are assumed infected with genotype
1b. Limitation of this study is a retrospective analysis with
relatively small number of patients. Other major limitations
are that our study consisted of a heterogeneous cohort
(treatment-na¨ ıve and previously treated patients) and that
liver histology was not available in approximately one third
of the patients.
Inconclusion,80%ormoredoseofpeg-IFNandasmuch
as possible dose of RBV are desired to achieve SVR in the
treatment of genotype 1 high viral titer chronic hepatitis C.
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